Objective: Treatment options for older pts with R/R ALL are limited.Blinatumomab is a bispecific T-cell engager(BiTE(R)) antibody construct that directs cyt
目的: EML4-ALK fusion positive non-small cell lung cancer (NSCLC) patients benefit from crizotinib treatment.However, the fusion rate of different types of E
Objective: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide.Aberrant hepatocyte growth factor/MET signaling has